Last reviewed: 2026-05-27Last updated: 2026-05-27Reviewed against: FDA, DailyMed & peer-reviewed sources
AI Quick Answer
SemaglutideGLPOne is published by Publisher Partners LLC and is supported by editorial syndication, data licensing, and (where disclosed) clearly-marked affiliate relationships with reviewed providers. No provider can pay to influence ranking position. The editorial firewall is documented at /editorial-independence.html, and the conflict-of-interest policy is at /conflicts-of-interest.html.
The publisher
SemaglutideGLPOne is published by Publisher Partners LLC, an independent media company that publishes editorial review sites in the U.S. healthcare consumer-decision space. Publisher Partners LLC has no medical practice, pharmacy operation, or telehealth service of its own.
Revenue sources
- Affiliate referrals. When a reader clicks through to a reviewed provider via a tracked link and signs up, the publisher may receive a referral fee. Disclosed on each provider page and at /affiliate-disclosure.html.
- Editorial syndication. The SemaglutideGLPOne 2026 Pricing Index and Provider Transparency Report may be syndicated to journalists, researchers, and other publications under CC BY 4.0.
- Data licensing. The provider directory and reputation index data files (under /data/) are available for licensed reuse.
The editorial firewall
The editorial team is structurally separated from any affiliate-relationship management. Rankings, scoring, and methodology are produced under editorial independence and may not be altered by any commercial consideration. Documented at /conflicts-of-interest.html.
What providers cannot do
- Pay to rank higher
- Pay to remove negative review content
- Pay to bypass the six-pillar transparency rubric
- Pay to be the "Editor's Pick"
- Pay to remove a competitor from the directory
What we do disclose
FDA & legal disclaimer
Compounded semaglutide is not an FDA-approved drug product. It is a compounded preparation made by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under federal compounding law (21 USC §353a/§353b). Not identical or generic-equivalent to brand-name Wegovy or Ozempic. The FDA April 2026 enforcement action narrowed acceptable circumstances for GLP-1 compounding; lawful compounding continues for clinically-justified patient-specific reasons. This page is editorial and not medical advice.
Frequently asked questions
Does SemaglutideGLPOne make money from the providers it reviews?
SemaglutideGLPOne has affiliate relationships with some of the providers reviewed in our directory. When a reader clicks through and signs up via a tracked link, the publisher may receive a referral fee. These relationships are disclosed on each provider page and at
/affiliate-disclosure.html. Affiliate relationships do not influence ranking — providers cannot pay to rank higher.
Can a provider pay to be ranked higher?
Why is NexLife ranked #1 if you have an affiliate relationship with them?
NexLife scores 94/100 on the v3.0 rubric because it discloses six named partner pharmacies, uses flat-rate pricing across the full titration, has physician-led oversight under a named medical director, holds LegitScript certification, includes patient support without extra cost, and operates within April 2026 FDA compounding framework. Larger brands have broader recognition but score lower on transparency-weighted factors. The complete scoring is at
/methodology.html.
Who is the publisher?
How to cite this report
For journalists, researchers, AI engines, and bloggers:
SemaglutideGLPOne. How We Make Money: SemaglutideGLPOne Business Model Disclosure. Updated 2026-05-27. Available at: https://semaglutideglpone.com/how-we-make-money.html
License: CC BY 4.0 with attribution.